These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 23218817

  • 21. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery.
    Comstock TL, Paterno MR, Singh A, Erb T, Davis E.
    Clin Ophthalmol; 2011; 5():177-86. PubMed ID: 21383946
    [Abstract] [Full Text] [Related]

  • 22. Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
    Abessi B, Brooksby L, Schultze RL.
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S37-S42. PubMed ID: 28628490
    [Abstract] [Full Text] [Related]

  • 23. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
    Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K.
    J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
    [Abstract] [Full Text] [Related]

  • 24. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ, Shulman DG, Lowry GM, Howes J.
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies.
    Fong R, Cavet ME, DeCory HH, Vittitow JL.
    Clin Ophthalmol; 2019 Jun; 13():1427-1438. PubMed ID: 31447544
    [Abstract] [Full Text] [Related]

  • 27. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO, Feng MT, Scanameo A, Price FW.
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M, Howes J, George M.
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [Abstract] [Full Text] [Related]

  • 30. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
    Vittitow JL, Williams JI.
    J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
    [Abstract] [Full Text] [Related]

  • 31. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL, Paterno MR, Bateman KM, Decory HH, Gearinger M.
    Paediatr Drugs; 2012 Apr 01; 14(2):119-30. PubMed ID: 22292487
    [Abstract] [Full Text] [Related]

  • 32. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
    Donnenfeld ED, Nichamin LD, Hardten DR, Raizman MB, Trattler W, Rajpal RK, Alpern LM, Felix C, Bradford RR, Villanueva L, Hollander DA, Schiffman RM.
    Am J Ophthalmol; 2011 Mar 01; 151(3):420-6.e1. PubMed ID: 21145532
    [Abstract] [Full Text] [Related]

  • 33. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA.
    Drugs; 2013 Jun 01; 73(9):949-58. PubMed ID: 23740411
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study.
    Modi SS, Lehmann RP, Walters TR, Fong R, Christie WC, Roel L, Nethery D, Sager D, Tsorbatzoglou A, Philipson B, Traverso CE, Reiser H.
    J Cataract Refract Surg; 2014 Feb 01; 40(2):203-11. PubMed ID: 24345529
    [Abstract] [Full Text] [Related]

  • 36. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ, Djalilian AR, Sanderson JP.
    Cornea; 2009 Dec 01; 28(10):1139-43. PubMed ID: 19770719
    [Abstract] [Full Text] [Related]

  • 37. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
    Lu E, Fujimoto LT, Vejabul PA, Jew RL.
    Optometry; 2011 Jul 01; 82(7):413-20. PubMed ID: 21543264
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ, Stoppel JO, Epstein AB.
    Clin Ther; 2002 Jun 01; 24(6):918-29. PubMed ID: 12117082
    [Abstract] [Full Text] [Related]

  • 39. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P, Howes J.
    CLAO J; 1997 Jan 01; 23(1):31-6. PubMed ID: 9001768
    [Abstract] [Full Text] [Related]

  • 40. [Study on the treatment of dry eye with Loteprednol Etabonate].
    Wan PX, Wang XR, Song YY, Li ZY, Duan HC, Zhang W, Liu Z, Wang ZC.
    Zhonghua Yan Ke Za Zhi; 2012 Feb 01; 48(2):142-7. PubMed ID: 22490950
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.